Systemic biomarkers of exposure associated with ENDS use: a scoping review

Marzena Hiler1, Anna-Sophie Weidner2, Lynn C Hull2

  • 1Center for Tobacco Products, Office of Science, US Food and Drug Administration, Silver Spring, Maryland, USA Marzena.Hiler@fda.hhs.gov.

Tobacco Control
|November 4, 2021
PubMed
Abstract